Dissecting disease tolerance in Plasmodium vivax malaria using the systemic degree of inflammatory perturbation

Homeostatic perturbation caused by infection fosters two major defense strategies, resistance and tolerance, which promote the host's survival. Resistance relates to the ability of the host to restrict the pathogen load. Tolerance minimizes collateral tissue damage without directly affecting pa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PLoS neglected tropical diseases 2021-11, Vol.15 (11), p.e0009886-e0009886
Hauptverfasser: Vinhaes, Caian L, Carmo, Thomas A, Queiroz, Artur T L, Fukutani, Kiyoshi F, Araújo-Pereira, Mariana, Arriaga, María B, Lacerda, Marcus V G, Barral-Netto, Manoel, Andrade, Bruno B
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e0009886
container_issue 11
container_start_page e0009886
container_title PLoS neglected tropical diseases
container_volume 15
creator Vinhaes, Caian L
Carmo, Thomas A
Queiroz, Artur T L
Fukutani, Kiyoshi F
Araújo-Pereira, Mariana
Arriaga, María B
Lacerda, Marcus V G
Barral-Netto, Manoel
Andrade, Bruno B
description Homeostatic perturbation caused by infection fosters two major defense strategies, resistance and tolerance, which promote the host's survival. Resistance relates to the ability of the host to restrict the pathogen load. Tolerance minimizes collateral tissue damage without directly affecting pathogen fitness. These concepts have been explored mechanistically in murine models of malaria but only superficially in human disease. Indeed, individuals infected with Plasmodium vivax may present with asymptomatic malaria, only mild symptoms, or be severely ill. We and others have reported a diverse repertoire of immunopathological events that potentially underly susceptibility to disease severity in vivax malaria. Nevertheless, the combined epidemiologic, clinical, parasitological, and immunologic features associated with defining the disease outcomes are still not fully understood. In the present study, we perform an extensive outlining of cytokines and inflammatory proteins in plasma samples from a cohort of individuals from the Brazilian Amazon infected with P. vivax and presenting with asymptomatic (n = 108) or symptomatic (n = 134) disease (106 with mild presentation and 28 with severe malaria), as well as from uninfected endemic controls (n = 128) to elucidate these gaps further. We employ highly multidimensional Systems Immunology analyses using the molecular degree of perturbation to reveal nuances of a unique profile of systemic inflammation and imbalanced immune activation directly linked to disease severity as well as with other clinical and epidemiologic characteristics. Additionally, our findings reveal that the main factor associated with severe cases of P. vivax infection was the number of symptoms, despite of a lower global inflammatory perturbation and parasitemia. In these participants, the number of symptoms directly correlated with perturbation of markers of inflammation and tissue damage. On the other hand, the main factor associated with non-severe infections was the parasitemia values, that correlated only with perturbation of inflammatory markers, such as IL-4 and IL-1β, with a relatively lower number of symptoms. These observations suggest that some persons present severe vivax regardless of pathogen burden and global inflammatory perturbation. Such patients are thus little tolerant to P. vivax infection and show higher susceptibility to disrupt homeostasis and consequently exhibit more clinical manifestations. Other persons are capable to
doi_str_mv 10.1371/journal.pntd.0009886
format Article
fullrecord <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2610942574</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A685871731</galeid><doaj_id>oai_doaj_org_article_433bd63dea5b4891b15c41708e8ba517</doaj_id><sourcerecordid>A685871731</sourcerecordid><originalsourceid>FETCH-LOGICAL-c585t-6eaf81b004187c1ea94027edb99065670f49a2cc34390a8ba6a585c5ea1acc6c3</originalsourceid><addsrcrecordid>eNptkl2L1DAUhoso7rr6D0QLgngzY9IkTXMjLOvXwoJe6HU4TU9nMqTNmKSD8-_NON1lRrxKSJ73PZ9F8ZKSJWWSvt_4KYzgltsxdUtCiGqa-lFxSRUTi0oy8fjkflE8i3FDiFCioU-LC8ZlJWlFLwv_0caIJtlxVXY2IkQsk3cYYDRY2rH87iAOvrPTUO7sDn6XAzgIFsopHjRpjWXcx4SDNWWHq4BY-j4LewfDAMmHfbnFkKbQQrJ-fF486cFFfDGfV8XPz59-3Hxd3H37cntzfbcwohFpUSP0DW0J4bSRhiIoTiqJXasUqUUtSc8VVMYwzhSBpoUass4IBArG1IZdFa-Pvlvno557FXVVU6J4JSTPxO2R6Dxs9DbYAcJee7D674MPKw0hWeNQc8barmYdgmh5o2hLheFUkgZzZEFl9vowR5vaATuDYwrgzkzPf0a71iu_041oVEVFNng3GwT_a8KY9GCjQedgRD_lvIVihAtJSUbf_IP-v7qZWkEuII_D57jmYKqv6xxV5qxppt6eUGsEl9bRu-kwqXgO8iNogo8xYP9QGyX6sI73SejDOup5HbPs1WlfHkT3-8f-ABjF3mk</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2610942574</pqid></control><display><type>article</type><title>Dissecting disease tolerance in Plasmodium vivax malaria using the systemic degree of inflammatory perturbation</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><source>Public Library of Science (PLoS)</source><creator>Vinhaes, Caian L ; Carmo, Thomas A ; Queiroz, Artur T L ; Fukutani, Kiyoshi F ; Araújo-Pereira, Mariana ; Arriaga, María B ; Lacerda, Marcus V G ; Barral-Netto, Manoel ; Andrade, Bruno B</creator><creatorcontrib>Vinhaes, Caian L ; Carmo, Thomas A ; Queiroz, Artur T L ; Fukutani, Kiyoshi F ; Araújo-Pereira, Mariana ; Arriaga, María B ; Lacerda, Marcus V G ; Barral-Netto, Manoel ; Andrade, Bruno B</creatorcontrib><description>Homeostatic perturbation caused by infection fosters two major defense strategies, resistance and tolerance, which promote the host's survival. Resistance relates to the ability of the host to restrict the pathogen load. Tolerance minimizes collateral tissue damage without directly affecting pathogen fitness. These concepts have been explored mechanistically in murine models of malaria but only superficially in human disease. Indeed, individuals infected with Plasmodium vivax may present with asymptomatic malaria, only mild symptoms, or be severely ill. We and others have reported a diverse repertoire of immunopathological events that potentially underly susceptibility to disease severity in vivax malaria. Nevertheless, the combined epidemiologic, clinical, parasitological, and immunologic features associated with defining the disease outcomes are still not fully understood. In the present study, we perform an extensive outlining of cytokines and inflammatory proteins in plasma samples from a cohort of individuals from the Brazilian Amazon infected with P. vivax and presenting with asymptomatic (n = 108) or symptomatic (n = 134) disease (106 with mild presentation and 28 with severe malaria), as well as from uninfected endemic controls (n = 128) to elucidate these gaps further. We employ highly multidimensional Systems Immunology analyses using the molecular degree of perturbation to reveal nuances of a unique profile of systemic inflammation and imbalanced immune activation directly linked to disease severity as well as with other clinical and epidemiologic characteristics. Additionally, our findings reveal that the main factor associated with severe cases of P. vivax infection was the number of symptoms, despite of a lower global inflammatory perturbation and parasitemia. In these participants, the number of symptoms directly correlated with perturbation of markers of inflammation and tissue damage. On the other hand, the main factor associated with non-severe infections was the parasitemia values, that correlated only with perturbation of inflammatory markers, such as IL-4 and IL-1β, with a relatively lower number of symptoms. These observations suggest that some persons present severe vivax regardless of pathogen burden and global inflammatory perturbation. Such patients are thus little tolerant to P. vivax infection and show higher susceptibility to disrupt homeostasis and consequently exhibit more clinical manifestations. Other persons are capable to tolerate higher parasitemia with lower inflammatory perturbation and fewer symptoms, developing non-severe malaria. The analytical approach presented here has capability to define in more details the determinants of disease tolerance in vivax malaria.</description><identifier>ISSN: 1935-2735</identifier><identifier>ISSN: 1935-2727</identifier><identifier>EISSN: 1935-2735</identifier><identifier>DOI: 10.1371/journal.pntd.0009886</identifier><identifier>PMID: 34727121</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adaptation ; Adult ; Animal models ; Asymptomatic ; Biological markers ; Biology and Life Sciences ; Biomarkers ; Brazil ; Chemokines ; Cohorts ; Creatinine ; Cytokines ; Damage ; Damage tolerance ; Diagnosis ; Diagnostic tests ; Disease susceptibility ; Disease tolerance ; Epidemiology ; Evaluation ; Female ; Health aspects ; Homeostasis ; Human diseases ; Humans ; Identification and classification ; IL-1β ; Immune response ; Immunological tolerance ; Immunology ; Infections ; Inflammation ; Interleukin 4 ; Interleukin-1beta - genetics ; Interleukin-1beta - immunology ; Interleukin-4 - genetics ; Interleukin-4 - immunology ; Laboratories ; Ligands ; Malaria ; Malaria, Vivax - genetics ; Malaria, Vivax - immunology ; Malaria, Vivax - parasitology ; Male ; Markers ; Medicine and Health Sciences ; Microscopy ; Middle Aged ; Parasitemia ; Parasites ; Parasitic diseases ; Pathogens ; Perturbation ; Physiological aspects ; Plasma ; Plasmodium vivax ; Plasmodium vivax - genetics ; Plasmodium vivax - physiology ; Polymerase chain reaction ; Retrospective Studies ; Severity of Illness Index ; Signs and symptoms ; Survival ; Symptoms ; Tissue ; Tissues ; Tolerance ; Tropical diseases ; Tumor necrosis factor-TNF ; Vector-borne diseases ; Young Adult</subject><ispartof>PLoS neglected tropical diseases, 2021-11, Vol.15 (11), p.e0009886-e0009886</ispartof><rights>COPYRIGHT 2021 Public Library of Science</rights><rights>2021 Vinhaes et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 Vinhaes et al 2021 Vinhaes et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c585t-6eaf81b004187c1ea94027edb99065670f49a2cc34390a8ba6a585c5ea1acc6c3</citedby><cites>FETCH-LOGICAL-c585t-6eaf81b004187c1ea94027edb99065670f49a2cc34390a8ba6a585c5ea1acc6c3</cites><orcidid>0000-0001-6883-8422 ; 0000-0002-1141-1580 ; 0000-0001-6833-3811 ; 0000-0003-3374-9985 ; 0000-0002-5823-7903 ; 0000-0001-8458-9315 ; 0000-0003-2223-0918 ; 0000-0003-3370-7128</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589215/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589215/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79569,79570</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34727121$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vinhaes, Caian L</creatorcontrib><creatorcontrib>Carmo, Thomas A</creatorcontrib><creatorcontrib>Queiroz, Artur T L</creatorcontrib><creatorcontrib>Fukutani, Kiyoshi F</creatorcontrib><creatorcontrib>Araújo-Pereira, Mariana</creatorcontrib><creatorcontrib>Arriaga, María B</creatorcontrib><creatorcontrib>Lacerda, Marcus V G</creatorcontrib><creatorcontrib>Barral-Netto, Manoel</creatorcontrib><creatorcontrib>Andrade, Bruno B</creatorcontrib><title>Dissecting disease tolerance in Plasmodium vivax malaria using the systemic degree of inflammatory perturbation</title><title>PLoS neglected tropical diseases</title><addtitle>PLoS Negl Trop Dis</addtitle><description>Homeostatic perturbation caused by infection fosters two major defense strategies, resistance and tolerance, which promote the host's survival. Resistance relates to the ability of the host to restrict the pathogen load. Tolerance minimizes collateral tissue damage without directly affecting pathogen fitness. These concepts have been explored mechanistically in murine models of malaria but only superficially in human disease. Indeed, individuals infected with Plasmodium vivax may present with asymptomatic malaria, only mild symptoms, or be severely ill. We and others have reported a diverse repertoire of immunopathological events that potentially underly susceptibility to disease severity in vivax malaria. Nevertheless, the combined epidemiologic, clinical, parasitological, and immunologic features associated with defining the disease outcomes are still not fully understood. In the present study, we perform an extensive outlining of cytokines and inflammatory proteins in plasma samples from a cohort of individuals from the Brazilian Amazon infected with P. vivax and presenting with asymptomatic (n = 108) or symptomatic (n = 134) disease (106 with mild presentation and 28 with severe malaria), as well as from uninfected endemic controls (n = 128) to elucidate these gaps further. We employ highly multidimensional Systems Immunology analyses using the molecular degree of perturbation to reveal nuances of a unique profile of systemic inflammation and imbalanced immune activation directly linked to disease severity as well as with other clinical and epidemiologic characteristics. Additionally, our findings reveal that the main factor associated with severe cases of P. vivax infection was the number of symptoms, despite of a lower global inflammatory perturbation and parasitemia. In these participants, the number of symptoms directly correlated with perturbation of markers of inflammation and tissue damage. On the other hand, the main factor associated with non-severe infections was the parasitemia values, that correlated only with perturbation of inflammatory markers, such as IL-4 and IL-1β, with a relatively lower number of symptoms. These observations suggest that some persons present severe vivax regardless of pathogen burden and global inflammatory perturbation. Such patients are thus little tolerant to P. vivax infection and show higher susceptibility to disrupt homeostasis and consequently exhibit more clinical manifestations. Other persons are capable to tolerate higher parasitemia with lower inflammatory perturbation and fewer symptoms, developing non-severe malaria. The analytical approach presented here has capability to define in more details the determinants of disease tolerance in vivax malaria.</description><subject>Adaptation</subject><subject>Adult</subject><subject>Animal models</subject><subject>Asymptomatic</subject><subject>Biological markers</subject><subject>Biology and Life Sciences</subject><subject>Biomarkers</subject><subject>Brazil</subject><subject>Chemokines</subject><subject>Cohorts</subject><subject>Creatinine</subject><subject>Cytokines</subject><subject>Damage</subject><subject>Damage tolerance</subject><subject>Diagnosis</subject><subject>Diagnostic tests</subject><subject>Disease susceptibility</subject><subject>Disease tolerance</subject><subject>Epidemiology</subject><subject>Evaluation</subject><subject>Female</subject><subject>Health aspects</subject><subject>Homeostasis</subject><subject>Human diseases</subject><subject>Humans</subject><subject>Identification and classification</subject><subject>IL-1β</subject><subject>Immune response</subject><subject>Immunological tolerance</subject><subject>Immunology</subject><subject>Infections</subject><subject>Inflammation</subject><subject>Interleukin 4</subject><subject>Interleukin-1beta - genetics</subject><subject>Interleukin-1beta - immunology</subject><subject>Interleukin-4 - genetics</subject><subject>Interleukin-4 - immunology</subject><subject>Laboratories</subject><subject>Ligands</subject><subject>Malaria</subject><subject>Malaria, Vivax - genetics</subject><subject>Malaria, Vivax - immunology</subject><subject>Malaria, Vivax - parasitology</subject><subject>Male</subject><subject>Markers</subject><subject>Medicine and Health Sciences</subject><subject>Microscopy</subject><subject>Middle Aged</subject><subject>Parasitemia</subject><subject>Parasites</subject><subject>Parasitic diseases</subject><subject>Pathogens</subject><subject>Perturbation</subject><subject>Physiological aspects</subject><subject>Plasma</subject><subject>Plasmodium vivax</subject><subject>Plasmodium vivax - genetics</subject><subject>Plasmodium vivax - physiology</subject><subject>Polymerase chain reaction</subject><subject>Retrospective Studies</subject><subject>Severity of Illness Index</subject><subject>Signs and symptoms</subject><subject>Survival</subject><subject>Symptoms</subject><subject>Tissue</subject><subject>Tissues</subject><subject>Tolerance</subject><subject>Tropical diseases</subject><subject>Tumor necrosis factor-TNF</subject><subject>Vector-borne diseases</subject><subject>Young Adult</subject><issn>1935-2735</issn><issn>1935-2727</issn><issn>1935-2735</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNptkl2L1DAUhoso7rr6D0QLgngzY9IkTXMjLOvXwoJe6HU4TU9nMqTNmKSD8-_NON1lRrxKSJ73PZ9F8ZKSJWWSvt_4KYzgltsxdUtCiGqa-lFxSRUTi0oy8fjkflE8i3FDiFCioU-LC8ZlJWlFLwv_0caIJtlxVXY2IkQsk3cYYDRY2rH87iAOvrPTUO7sDn6XAzgIFsopHjRpjWXcx4SDNWWHq4BY-j4LewfDAMmHfbnFkKbQQrJ-fF486cFFfDGfV8XPz59-3Hxd3H37cntzfbcwohFpUSP0DW0J4bSRhiIoTiqJXasUqUUtSc8VVMYwzhSBpoUass4IBArG1IZdFa-Pvlvno557FXVVU6J4JSTPxO2R6Dxs9DbYAcJee7D674MPKw0hWeNQc8barmYdgmh5o2hLheFUkgZzZEFl9vowR5vaATuDYwrgzkzPf0a71iu_041oVEVFNng3GwT_a8KY9GCjQedgRD_lvIVihAtJSUbf_IP-v7qZWkEuII_D57jmYKqv6xxV5qxppt6eUGsEl9bRu-kwqXgO8iNogo8xYP9QGyX6sI73SejDOup5HbPs1WlfHkT3-8f-ABjF3mk</recordid><startdate>20211101</startdate><enddate>20211101</enddate><creator>Vinhaes, Caian L</creator><creator>Carmo, Thomas A</creator><creator>Queiroz, Artur T L</creator><creator>Fukutani, Kiyoshi F</creator><creator>Araújo-Pereira, Mariana</creator><creator>Arriaga, María B</creator><creator>Lacerda, Marcus V G</creator><creator>Barral-Netto, Manoel</creator><creator>Andrade, Bruno B</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7SS</scope><scope>7T2</scope><scope>7T7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>F1W</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>H95</scope><scope>H97</scope><scope>K9.</scope><scope>L.G</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>P64</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-6883-8422</orcidid><orcidid>https://orcid.org/0000-0002-1141-1580</orcidid><orcidid>https://orcid.org/0000-0001-6833-3811</orcidid><orcidid>https://orcid.org/0000-0003-3374-9985</orcidid><orcidid>https://orcid.org/0000-0002-5823-7903</orcidid><orcidid>https://orcid.org/0000-0001-8458-9315</orcidid><orcidid>https://orcid.org/0000-0003-2223-0918</orcidid><orcidid>https://orcid.org/0000-0003-3370-7128</orcidid></search><sort><creationdate>20211101</creationdate><title>Dissecting disease tolerance in Plasmodium vivax malaria using the systemic degree of inflammatory perturbation</title><author>Vinhaes, Caian L ; Carmo, Thomas A ; Queiroz, Artur T L ; Fukutani, Kiyoshi F ; Araújo-Pereira, Mariana ; Arriaga, María B ; Lacerda, Marcus V G ; Barral-Netto, Manoel ; Andrade, Bruno B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c585t-6eaf81b004187c1ea94027edb99065670f49a2cc34390a8ba6a585c5ea1acc6c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adaptation</topic><topic>Adult</topic><topic>Animal models</topic><topic>Asymptomatic</topic><topic>Biological markers</topic><topic>Biology and Life Sciences</topic><topic>Biomarkers</topic><topic>Brazil</topic><topic>Chemokines</topic><topic>Cohorts</topic><topic>Creatinine</topic><topic>Cytokines</topic><topic>Damage</topic><topic>Damage tolerance</topic><topic>Diagnosis</topic><topic>Diagnostic tests</topic><topic>Disease susceptibility</topic><topic>Disease tolerance</topic><topic>Epidemiology</topic><topic>Evaluation</topic><topic>Female</topic><topic>Health aspects</topic><topic>Homeostasis</topic><topic>Human diseases</topic><topic>Humans</topic><topic>Identification and classification</topic><topic>IL-1β</topic><topic>Immune response</topic><topic>Immunological tolerance</topic><topic>Immunology</topic><topic>Infections</topic><topic>Inflammation</topic><topic>Interleukin 4</topic><topic>Interleukin-1beta - genetics</topic><topic>Interleukin-1beta - immunology</topic><topic>Interleukin-4 - genetics</topic><topic>Interleukin-4 - immunology</topic><topic>Laboratories</topic><topic>Ligands</topic><topic>Malaria</topic><topic>Malaria, Vivax - genetics</topic><topic>Malaria, Vivax - immunology</topic><topic>Malaria, Vivax - parasitology</topic><topic>Male</topic><topic>Markers</topic><topic>Medicine and Health Sciences</topic><topic>Microscopy</topic><topic>Middle Aged</topic><topic>Parasitemia</topic><topic>Parasites</topic><topic>Parasitic diseases</topic><topic>Pathogens</topic><topic>Perturbation</topic><topic>Physiological aspects</topic><topic>Plasma</topic><topic>Plasmodium vivax</topic><topic>Plasmodium vivax - genetics</topic><topic>Plasmodium vivax - physiology</topic><topic>Polymerase chain reaction</topic><topic>Retrospective Studies</topic><topic>Severity of Illness Index</topic><topic>Signs and symptoms</topic><topic>Survival</topic><topic>Symptoms</topic><topic>Tissue</topic><topic>Tissues</topic><topic>Tolerance</topic><topic>Tropical diseases</topic><topic>Tumor necrosis factor-TNF</topic><topic>Vector-borne diseases</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vinhaes, Caian L</creatorcontrib><creatorcontrib>Carmo, Thomas A</creatorcontrib><creatorcontrib>Queiroz, Artur T L</creatorcontrib><creatorcontrib>Fukutani, Kiyoshi F</creatorcontrib><creatorcontrib>Araújo-Pereira, Mariana</creatorcontrib><creatorcontrib>Arriaga, María B</creatorcontrib><creatorcontrib>Lacerda, Marcus V G</creatorcontrib><creatorcontrib>Barral-Netto, Manoel</creatorcontrib><creatorcontrib>Andrade, Bruno B</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Aquatic Science &amp; Fisheries Abstracts (ASFA) 1: Biological Sciences &amp; Living Resources</collection><collection>Aquatic Science &amp; Fisheries Abstracts (ASFA) 3: Aquatic Pollution &amp; Environmental Quality</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Aquatic Science &amp; Fisheries Abstracts (ASFA) Professional</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest Health &amp; Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health &amp; Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PLoS neglected tropical diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vinhaes, Caian L</au><au>Carmo, Thomas A</au><au>Queiroz, Artur T L</au><au>Fukutani, Kiyoshi F</au><au>Araújo-Pereira, Mariana</au><au>Arriaga, María B</au><au>Lacerda, Marcus V G</au><au>Barral-Netto, Manoel</au><au>Andrade, Bruno B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dissecting disease tolerance in Plasmodium vivax malaria using the systemic degree of inflammatory perturbation</atitle><jtitle>PLoS neglected tropical diseases</jtitle><addtitle>PLoS Negl Trop Dis</addtitle><date>2021-11-01</date><risdate>2021</risdate><volume>15</volume><issue>11</issue><spage>e0009886</spage><epage>e0009886</epage><pages>e0009886-e0009886</pages><issn>1935-2735</issn><issn>1935-2727</issn><eissn>1935-2735</eissn><abstract>Homeostatic perturbation caused by infection fosters two major defense strategies, resistance and tolerance, which promote the host's survival. Resistance relates to the ability of the host to restrict the pathogen load. Tolerance minimizes collateral tissue damage without directly affecting pathogen fitness. These concepts have been explored mechanistically in murine models of malaria but only superficially in human disease. Indeed, individuals infected with Plasmodium vivax may present with asymptomatic malaria, only mild symptoms, or be severely ill. We and others have reported a diverse repertoire of immunopathological events that potentially underly susceptibility to disease severity in vivax malaria. Nevertheless, the combined epidemiologic, clinical, parasitological, and immunologic features associated with defining the disease outcomes are still not fully understood. In the present study, we perform an extensive outlining of cytokines and inflammatory proteins in plasma samples from a cohort of individuals from the Brazilian Amazon infected with P. vivax and presenting with asymptomatic (n = 108) or symptomatic (n = 134) disease (106 with mild presentation and 28 with severe malaria), as well as from uninfected endemic controls (n = 128) to elucidate these gaps further. We employ highly multidimensional Systems Immunology analyses using the molecular degree of perturbation to reveal nuances of a unique profile of systemic inflammation and imbalanced immune activation directly linked to disease severity as well as with other clinical and epidemiologic characteristics. Additionally, our findings reveal that the main factor associated with severe cases of P. vivax infection was the number of symptoms, despite of a lower global inflammatory perturbation and parasitemia. In these participants, the number of symptoms directly correlated with perturbation of markers of inflammation and tissue damage. On the other hand, the main factor associated with non-severe infections was the parasitemia values, that correlated only with perturbation of inflammatory markers, such as IL-4 and IL-1β, with a relatively lower number of symptoms. These observations suggest that some persons present severe vivax regardless of pathogen burden and global inflammatory perturbation. Such patients are thus little tolerant to P. vivax infection and show higher susceptibility to disrupt homeostasis and consequently exhibit more clinical manifestations. Other persons are capable to tolerate higher parasitemia with lower inflammatory perturbation and fewer symptoms, developing non-severe malaria. The analytical approach presented here has capability to define in more details the determinants of disease tolerance in vivax malaria.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>34727121</pmid><doi>10.1371/journal.pntd.0009886</doi><orcidid>https://orcid.org/0000-0001-6883-8422</orcidid><orcidid>https://orcid.org/0000-0002-1141-1580</orcidid><orcidid>https://orcid.org/0000-0001-6833-3811</orcidid><orcidid>https://orcid.org/0000-0003-3374-9985</orcidid><orcidid>https://orcid.org/0000-0002-5823-7903</orcidid><orcidid>https://orcid.org/0000-0001-8458-9315</orcidid><orcidid>https://orcid.org/0000-0003-2223-0918</orcidid><orcidid>https://orcid.org/0000-0003-3370-7128</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1935-2735
ispartof PLoS neglected tropical diseases, 2021-11, Vol.15 (11), p.e0009886-e0009886
issn 1935-2735
1935-2727
1935-2735
language eng
recordid cdi_plos_journals_2610942574
source MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access; Public Library of Science (PLoS)
subjects Adaptation
Adult
Animal models
Asymptomatic
Biological markers
Biology and Life Sciences
Biomarkers
Brazil
Chemokines
Cohorts
Creatinine
Cytokines
Damage
Damage tolerance
Diagnosis
Diagnostic tests
Disease susceptibility
Disease tolerance
Epidemiology
Evaluation
Female
Health aspects
Homeostasis
Human diseases
Humans
Identification and classification
IL-1β
Immune response
Immunological tolerance
Immunology
Infections
Inflammation
Interleukin 4
Interleukin-1beta - genetics
Interleukin-1beta - immunology
Interleukin-4 - genetics
Interleukin-4 - immunology
Laboratories
Ligands
Malaria
Malaria, Vivax - genetics
Malaria, Vivax - immunology
Malaria, Vivax - parasitology
Male
Markers
Medicine and Health Sciences
Microscopy
Middle Aged
Parasitemia
Parasites
Parasitic diseases
Pathogens
Perturbation
Physiological aspects
Plasma
Plasmodium vivax
Plasmodium vivax - genetics
Plasmodium vivax - physiology
Polymerase chain reaction
Retrospective Studies
Severity of Illness Index
Signs and symptoms
Survival
Symptoms
Tissue
Tissues
Tolerance
Tropical diseases
Tumor necrosis factor-TNF
Vector-borne diseases
Young Adult
title Dissecting disease tolerance in Plasmodium vivax malaria using the systemic degree of inflammatory perturbation
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T17%3A49%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dissecting%20disease%20tolerance%20in%20Plasmodium%20vivax%20malaria%20using%20the%20systemic%20degree%20of%20inflammatory%20perturbation&rft.jtitle=PLoS%20neglected%20tropical%20diseases&rft.au=Vinhaes,%20Caian%20L&rft.date=2021-11-01&rft.volume=15&rft.issue=11&rft.spage=e0009886&rft.epage=e0009886&rft.pages=e0009886-e0009886&rft.issn=1935-2735&rft.eissn=1935-2735&rft_id=info:doi/10.1371/journal.pntd.0009886&rft_dat=%3Cgale_plos_%3EA685871731%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2610942574&rft_id=info:pmid/34727121&rft_galeid=A685871731&rft_doaj_id=oai_doaj_org_article_433bd63dea5b4891b15c41708e8ba517&rfr_iscdi=true